The DOI matches its Crossref record.
Immunoablative High-Dose Cyclophosphamide without Stem-Cell Rescue for Refractory, Severe Autoimmune Disease
Abstract
BACKGROUND: Immunoablative high-dose cyclophosphamide without stem-cell rescue induces durable, complete remission in most patients with aplastic anemia. OBJECTIVE: To determine the efficacy of high-dose cyclophosphamide in various refractory, severe autoimmune diseases. DESIGN: Prospective phase II study. SETTING: Johns Hopkins University (Baltimore, Maryland) and Hahnemann University (Philadelphia, Pennsylvania). PATIENTS: Eight patients with refractory, severe autoimmune disease. INTERVENTION: Immunoablative high-dose cyclophosphamide (50 mg/kg of body weight per day) for 4 consecutive days. MEASUREMENTS: Clinical and laboratory variables of autoimmune disease. RESULTS: Seven patients improved markedly: Five achieved complete remission and two achieved partial remission. Four patients have remained in continuous complete remission for 3 to 21 months, and two patients in partial remission continue to improve after 14 and 19 months of follow-up. High-dose cyclophosphamide was well tolerated; median times to a neutrophil count of 0.5 x 10(9) cells/L and platelet transfusion independence were 17 and 16 days, respectively. CONCLUSIONS: Immunoablative high-dose cyclophosphamide without stem-cell rescue can induce complete remission in patients with refractory, severe autoimmune disease. Reemergence of marrow function is similar to that seen after autologous transplantation and does not carry the risk for reinfusion of autoaggressive lymphocytes with the autograft.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cyclophosphamide and cancer: golden anniversary
Emadi, A., Jones, R. J., & Brodsky, R. A. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.146 · Cited by 1,050
Self-citationBoumpas, D. T., Furie, R., Manzi, S., Illei, G. G., Wallace, D. J., Balow, J. E., Vaishnaw, A., & on behalf of the BG9588 Lupus Nephritis Trial Group (2003) · Arthritis & Rheumatism · doi:10.1002/art.10856 · Cited by 618
Illei, G. G., Austin, H. A., Crane, M., Collins, L., Gourley, M. F., Yarboro, C. H., Vaughan, E. M., Kuroiwa, T., Danning, C. L., Steinberg, A. D., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-4-200108210-00009 · Cited by 492
O'Donnell, P. V., Luznik, L., Jones, R. J., Vogelsang, G. B., Leffell, M. S., Phelps, M., Rhubart, P., Cowan, K., Piantadosi, S., & Fuchs, E. J. (2002) · Biology of Blood and Marrow Transplantation · doi:10.1053/bbmt.2002.v8.pm12171484 · Cited by 491
Self-citationNorton, A., & Roberts, I. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05809.x · Cited by 261
Metadata
- Authors
- Brodsky, R. A., Petri, M., Smith, B. D., Seifter, E. J., Spivak, J. L., Styler, M., Dang, C. V., Brodsky, I., & Jones, R. J.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1998-12-15
- Volume
- 129
- Issue
- 12
- Pages
- 1031-1035
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1968030467
- Cited by
- 236
- References
- 0
- FWCI
- 15.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunoablative High-Dose Cyclophosphamide without Stem-Cell Rescue for Refractory, Severe Autoimmune Disease. https://app.cochat.ai/papers/10.7326/0003-4819-129-12-199812150-00007
- The paper
- Brodsky, R. A., Petri, M., Smith, B. D., Seifter, E. J., Spivak, J. L., Styler, M., Dang, C. V., Brodsky, I., & Jones, R. J. (1998). Immunoablative High-Dose Cyclophosphamide without Stem-Cell Rescue for Refractory, Severe Autoimmune Disease. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-129-12-199812150-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.